Rezolute, Inc.
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation
Company newsroom
Rezolute, Inc.
NASDAQ:RZLT
1 releases